Headlines about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intec Pharma earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.6478711150897 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of NASDAQ NTEC traded down $0.05 during mid-day trading on Friday, reaching $3.95. The company had a trading volume of 87,402 shares, compared to its average volume of 61,827. Intec Pharma has a twelve month low of $3.88 and a twelve month high of $9.80. The company has a market capitalization of $131.30 million, a PE ratio of -2.39 and a beta of 1.17.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.13). analysts anticipate that Intec Pharma will post -1.26 EPS for the current fiscal year.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.